<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tblu6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Variance estimate</th><th>F test statistic F(1,64) <break/>(shRNA, Dox, <break/>Drug interaction)</th><th>Partial &#951;<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample <break/>size <break/>(32 groups)</th></tr></thead><tbody><tr><td rowspan="4">Normalized pMEK <break/>in shBRAF or <break/>shCRAF cells treated <break/>with or&#160;without Dox <break/>and varying&#160;doses <break/>of GDC-0879&#160;or <break/>PLX4720</td><td>2%</td><td>2513.61</td><td>0.97245</td><td>5.94063</td><td>99.9%</td><td>96</td></tr><tr><td>15%</td><td>45.6115</td><td>0.39616</td><td>0.80999</td><td>99.9%</td><td>96</td></tr><tr><td>28%</td><td>13.8318</td><td>0.16726</td><td>0.44817</td><td>99.1%</td><td>96</td></tr><tr><td>40%</td><td>7.3203</td><td>0.09650</td><td>0.32681</td><td>88.4%</td><td>96</td></tr></tbody></table></table-wrap>